HR 9676 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Examining Opioid Treatment Infrastructure Act of 2026
To direct the Comptroller General of the United States to evaluate and report on the inpatient and outpatient treatment capacity, availability, and needs of the United States with respect to opioid-use disorders, and for other purposes.
Summary
- Directs the Comptroller General to evaluate the treatment capacity, availability, and needs for opioid-use disorders across the United States.
- Requires the Comptroller General to submit a report to Congress within 24 months detailing findings on opioid treatment infrastructure.
- Requires the evaluation to assess both inpatient and outpatient treatment capacity, including detoxification, clinical stabilization, and rehabilitation programs.
- Requires the evaluation to identify geographical differences in treatment availability and assess treatment needs for specific populations including pregnant women, adolescents, and American Indians and Alaska Natives.
- Requires the evaluation to examine barriers to real-time reporting of overdose information and identify ways to overcome those barriers.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Foster, Bill [D-IL-11] (D-IL)
Money behind the sponsor
Top reported contributors to Bill Foster’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- FERMILAB $22,943
- NULL $18,250
- BOSTON UNIVERSITY $17,800
- UNIVERSITY OF CHICAGO $17,560
- NORTHWESTERN UNIVERSITY $17,476
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Bill Foster → · Outside spending →
Actions (2)
- Jul 14, 2026 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Jul 14, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
July 14, 2026
Mr. Foster introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To direct the Comptroller General of the United States to evaluate and report on the inpatient and outpatient treatment capacity, availability, and needs of the United States with respect to opioid-use disorders, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Examining Opioid Treatment Infrastructure Act of 2026”.
SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE FOR OPIOID-USE DISORDERS.
Not later than 24 months after the date of enactment of this Act, the Comptroller General of the United States shall initiate an evaluation of, and submit to Congress a report on, the inpatient and outpatient treatment capacity, availability, and needs of the United States with respect to opioid-use disorders, including, to the extent data are available—
(1) the capacity of acute residential or inpatient detoxification programs;
(2) the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs;
(3) the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents;
(4) geographical differences in the availability of residential and outpatient treatment and recovery options across the continuum of care;
(5) the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance-use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies;
(6) the number of patients in residential and specialty outpatient treatment services;
(7) an assessment of the need for residential and outpatient treatment across the continuum of care;
(8) the availability of residential and outpatient treatment programs to American Indians and Alaska Natives through an Indian health program (as defined by section 4 of the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
(9) the barriers (including technological barriers) at the Federal, State, and local levels to real-time reporting of de- identified information on drug overdoses and ways to overcome such barriers. <all>
Comments